Evidence map›Paper›PMID 34754993›Full record

ReviewJACC. Basic to translational science

Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction.

Luca Rosalia, Caglar Ozturk, Saeed Shoar, Yiling Fan, Grainne Malone, Faisal H Cheema, Claire Conway, Robert A Byrne, Garry P Duffy, Andrew Malone and 2 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JACC. Basic to translational science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Technological evolution ofFrontiers in physiology · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Luca RosaliaHealth Sciences and Technology Program, Harvard-Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Caglar OzturkInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Saeed ShoarHCA Healthcare, Houston, Texas, USA.
Yiling FanDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Grainne MaloneTissue Engineering Research Group (TERG), Department of Anatomy and Regenerative Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
Faisal H CheemaHCA Healthcare, Houston, Texas, USA.
Claire ConwayTissue Engineering Research Group (TERG), Department of Anatomy and Regenerative Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
Robert A ByrneDepartment of Cardiology, Mater Private Hospital, Dublin, Ireland.
Garry P DuffyTissue Engineering Research Group (TERG), Department of Anatomy and Regenerative Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
Andrew MaloneTissue Engineering Research Group (TERG), Department of Anatomy and Regenerative Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
Ellen T RocheHealth Sciences and Technology Program, Harvard-Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Aamir HameedTissue Engineering Research Group (TERG), Department of Anatomy and Regenerative Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
Royal College of Surgeons in Ireland · IEHarvard–MIT Division of Health Sciences and Technology · USHCA Healthcare · USMassachusetts Institute of Technology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Characterized by a rapidly increasing prevalence, elevated mortality and rehospitalization rates, and inadequacy of pharmaceutical therapies, heart failure with preserved ejection fraction (HFpEF) has motivated the widespread development of device-based solutions. HFpEF is a multifactorial disease of various etiologies and phenotypes, distinguished by diminished ventricular compliance, diastolic dysfunction, and symptoms of heart failure despite a normal ejection performance; these symptoms include pulmonary hypertension, limited cardiac reserve, autonomic imbalance, and exercise intolerance. Several types of atrial shunts, left ventricular expanders, stimulation-based therapies, and mechanical circulatory support devices are currently under development aiming to target one or more of these symptoms by addressing the associated mechanical or hemodynamic hallmarks. Although the majority of these solutions have shown promising results in clinical or preclinical studies, no device-based therapy has yet been approved for the treatment of patients with HFpEF. The purpose of this review is to discuss the rationale behind each of these devices and the findings from the initial testing phases, as well as the limitations and challenges associated with their clinical translation.

Indexed as

atrial shunt devicesBAT, baroreceptor activation therapyCCM, cardiac contractility modulationCRT, cardiac resynchronization therapyelectrostimulationheart failure devicesheart failure with preserved ejection fractionHF, heart failureHFmEF, heart failure with mid-range ejection fractionHFpEFHFpEF, heart failure with preserved ejection fractionHFrEF, heart failure with reduced ejection fractionIASD, Interatrial Shunt DeviceLAAD, left atrial assist deviceLAP, left atrial pressureleft ventricular expandersLVEF, left ventricular ejection fractionLV, left ventricularMCS, mechanical circulatory supportmechanical circulatory supportneuromodulationNYHA, New York Heart AssociationPCWP, pulmonary capillary wedge pressureQoL, quality of lifeTAA, transapical approach

Identifiers

PMID34754993
PMCPMC8559325
OpenAlexW3192788863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.